BRIMONIDINE TARTRATE Drug Patent Profile
✉ Email this page to a colleague
When do Brimonidine Tartrate patents expire, and when can generic versions of Brimonidine Tartrate launch?
Brimonidine Tartrate is a drug marketed by Padagis Israel, Alembic, Apotex, Bausch And Lomb, Dr Reddys Labs Sa, Indoco, Micro Labs, Rising, Sandoz, Somerset Theraps Llc, Teva Parenteral, Florida, Sentiss, and Upsher Smith Labs. and is included in twenty-one NDAs.
The generic ingredient in BRIMONIDINE TARTRATE is brimonidine tartrate; timolol maleate. There are eleven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the brimonidine tartrate; timolol maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Brimonidine Tartrate
A generic version of BRIMONIDINE TARTRATE was approved as brimonidine tartrate; timolol maleate by SANDOZ on April 4th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BRIMONIDINE TARTRATE?
- What are the global sales for BRIMONIDINE TARTRATE?
- What is Average Wholesale Price for BRIMONIDINE TARTRATE?
Summary for BRIMONIDINE TARTRATE
US Patents: | 0 |
Applicants: | 14 |
NDAs: | 21 |
Finished Product Suppliers / Packagers: | 12 |
Raw Ingredient (Bulk) Api Vendors: | 153 |
Clinical Trials: | 54 |
Patent Applications: | 1,657 |
Drug Prices: | Drug price information for BRIMONIDINE TARTRATE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for BRIMONIDINE TARTRATE |
What excipients (inactive ingredients) are in BRIMONIDINE TARTRATE? | BRIMONIDINE TARTRATE excipients list |
DailyMed Link: | BRIMONIDINE TARTRATE at DailyMed |
![BRIMONIDINE TARTRATE drug patent expirations Drug patent expirations by year for BRIMONIDINE TARTRATE](/p/graph/s/t/BRIMONIDINE_TARTRATE-patent-expirations.png)
![Drug Prices for BRIMONIDINE TARTRATE](/p/graph/drug-price/BRIMONIDINE+TARTRATE.png)
See drug prices for BRIMONIDINE TARTRATE
![Drug Sales Revenue Trends for BRIMONIDINE TARTRATE](/p/graph/drug-sales-revenues/BRIMONIDINE+TARTRATE.png)
Recent Clinical Trials for BRIMONIDINE TARTRATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tulane University | Phase 4 |
Visus Therapeutics | Phase 3 |
Optall Vision | Phase 1 |
Pharmacology for BRIMONIDINE TARTRATE
Drug Class | alpha-Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha-Agonists |
Medical Subject Heading (MeSH) Categories for BRIMONIDINE TARTRATE
Anatomical Therapeutic Chemical (ATC) Classes for BRIMONIDINE TARTRATE
Paragraph IV (Patent) Challenges for BRIMONIDINE TARTRATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
LUMIFY | Ophthalmic Solution | brimonidine tartrate | 0.025% | 208144 | 1 | 2021-07-12 |
MIRVASO | Topical Gel | brimonidine tartrate | 0.33% | 204708 | 1 | 2014-12-15 |
ALPHAGAN P | Ophthalmic Solution | brimonidine tartrate | 0.1% | 021770 | 1 | 2006-12-20 |
ALPHAGAN P | Ophthalmic Solution | brimonidine tartrate | 0.15% | 021262 | 1 | 2006-11-03 |
US Patents and Regulatory Information for BRIMONIDINE TARTRATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Padagis Israel | BRIMONIDINE TARTRATE | brimonidine tartrate | GEL;TOPICAL | 209158-001 | Sep 23, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Florida | BRIMONIDINE TARTRATE AND TIMOLOL MALEATE | brimonidine tartrate; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 201949-001 | Oct 4, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Dr Reddys Labs Sa | BRIMONIDINE TARTRATE | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 216361-001 | Feb 16, 2024 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apotex | BRIMONIDINE TARTRATE | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 078480-001 | Dec 21, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |